Read by QxMD icon Read

Genetic Vaccines and Therapy

Syyada Samra Jafri, Saliha Kiran, Syed Babar Jamal, Masaud Shah
No abstract text is available yet for this article.
October 23, 2012: Genetic Vaccines and Therapy
Sarfraz Ahmad, Paul Sweeney, Gerald C Sullivan, Mark Tangney
Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms, strong clinical evidence is still lacking...
October 9, 2012: Genetic Vaccines and Therapy
Henry Kajumbula, Wilson Byarugaba, Misaki Wayengera
UNLABELLED: <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Malaria causes immense human morbidity and mortality globally. The plasmodium species vivax and falciparum cause over 75 % clinical malaria cases. Until now, gene-based strategies against malaria have only been applied to plasmodium species and their mosquito-vector. Merozoites of these two respective plasmodium species target and invade red blood cells (RBCs) by using the duffy antigen receptor for chemokines (DARC), and Sialic Acid (SLC4A1) residues of the O-linked glycans of Glycophorin A...
August 31, 2012: Genetic Vaccines and Therapy
Rama Jayaraj, David Piedrafita, Terry Spithill, Peter Smooker
UNLABELLED: <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Liver fluke can infect cattle and sheep, and is also emerging as a human pathogen in developing countries. Cathepsin B (Cat B2) is a major cysteine protease secreted by the juvenile flukes. To enhance the immune responses of Cat B2, the cDNA sequence was fused with four different DNA vaccine vectors. The induced cellular and antibody responses were compared in vaccinated mice. METHODS: The following recombinant DNA vaccine constructs were constructed: empty vector VR1012 as negative control, cytoplasmic construct pVR1012 Cat B2, secretory construct pVR1020 Cat B2, chemokine-fused construct pMCP3 Cat B2 and lymph node targeting construct pCTLA-4 Cat B2...
August 31, 2012: Genetic Vaccines and Therapy
David Hallengärd, Andreas Bråve, Maria Isaguliants, Pontus Blomberg, Jenny Enger, Richard Stout, Alan King, Britta Wahren
UNLABELLED: <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of optimized delivery devices has been shown to enhance the potency of DNA vaccines. However, further optimization of DNA vaccine delivery is needed for this vaccine modality to ultimately be efficacious in humans. METHODS: Herein we evaluated antigen expression and immunogenicity after intradermal delivery of different doses of DNA vaccines by needle or by the Biojector jet-injection device, with or without the addition of electroporation (EP)...
August 8, 2012: Genetic Vaccines and Therapy
Syyada Samra Jafri, Saliha Kiran, Syed Babar Jamal, Masaud Shah
UNLABELLED: <AbstractText Label="BACKGROUND">Gp41 is an envelope glycoprotein of human immune deficiency virus (HIV). HIV viral glycoprotein gp41, present in complex with gp120, assists the viral entry into host cell. Over eighty thousands individuals are HIV infected in Pakistan which makes about 0.2% of 38.6 million infected patients worldwide. Hence, HIV gp41 protein sequences isolated in Pakistan were analyzed for the CD4 and CD8 T cells binding epitopes. RESULTS: Immunoinformatics tools were applied for the study of variant region of HIV gp41envelope protein...
June 20, 2012: Genetic Vaccines and Therapy
Sobia Idrees, Usman A Ashfaq
Dengue virus infection is a serious health problem infecting 2.5 billion people worldwide. Dengue is now endemic in more than 100 countries, including Pakistan. Each year hundreds of people get infected with dengue in Pakistan. Currently, there is no vaccine available for the prevention of Dengue virus infection due to four viral serotypes. Dengue infection can cause death of patients in its most severity, meanwhile many antiviral compounds are being tested against dengue virus infection to eradicate this disease but still there is a need to develop an efficient, low-cost and safe vaccine that can target all the four serotypes of dengue virus...
2012: Genetic Vaccines and Therapy
Ni-Chung Lee, Darin J Falk, Barry J Byrne, Thomas J Conlon, Nathalie Clement, Stacy Porvasnik, Marda L Jorgensen, Mark Potter, Kirsten E Erger, Rachael Watson, Steven C Ghivizzani, Hung-Chuan Chiu, Yin-Hsiu Chien, Wuh-Liang Hwu
BACKGROUND: The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones. METHODS: In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2 mCherry expression vectors (3...
2012: Genetic Vaccines and Therapy
Flávia Helena da Silva, Vanessa Gonçalves Pereira, Eduardo G Yasumura, Lígia Zacchi Tenório, Leonardo Pinto de Carvalho, Bianca Cristina Garcia Lisboa, Priscila Keiko Matsumoto, Roberta Sessa Stilhano, Vivian Y Samoto, Bruno Frederico Aguilar Calegare, Letícia de Campos Brandão, Vânia D'Almeida, Thaís Rm Filippo, Marimélia Porcionatto, Leny Toma, Helena Bonciani Nader, Valderez Bastos Valero, Melissa Camassola, Nance Beyer Nardi, Sang Won Han
BACKGROUND: Mucopolysaccharidosis type I (MPSI) is caused by a deficiency in alpha-L iduronidase (IDUA), which leads to lysosomal accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate. While the currently available therapies have good systemic effects, they only minimally affect the neurodegenerative process. Based on the neuroprotective and tissue regenerative properties of mesenchymal stem cells (MSCs), we hypothesized that the administration of MSCs transduced with a murine leukemia virus (MLV) vector expressing IDUA to IDUA KO mouse brains could reduce GAG deposition in the brain and, as a result, improve neurofunctionality, as measured by exploratory activity...
2012: Genetic Vaccines and Therapy
Masaud Shah, Sulaiman Shams, Ziaur Rahman
BACKGROUND: Countrywide 5.9 million, 0-11 Month old children are immunized annually by EPI (Expended Program on Immunization) against 8 vaccine preventable diseases including measles and so on. Unfortunately the basic immunity centers are not uniform throughout the country. Each center provides services to about 27000 people which is inadequate. The purpose of this study was to explore the development of EPI Pakistan in terms of immunization of measles. METHODS: Nucleotide sequences were analyzed by neighbor joining method (bootstrap test) using Bio- edit and MEGA-5 software to find evolutionary relationship between wild type measles strain and vaccine strain (Edmonston strain) used in Pakistan...
2012: Genetic Vaccines and Therapy
Sadia Butt, Muhammad Idrees, Irshad-Ur Rehman, Liaqat Ali, Abrar Hussain, Muhammad Ali, Naveed Ahmed, Sana Saleem, Madiha Fayyaz
BACKGROUND: Hepatitis C virus (HCV) infection is the leading cause of chronic hepatitis which progresses to hepatocellular carcinoma (HCC) afflicting > 170 million people worldwide. HCV 3a is the most common genotype (about 70% of all genotypes) circulating in Pakistan. Expression of HCV individual gene of 3a would facilitate therapeutic and vaccines strategies against chronic HCV and liver Cirrhosis. The aim of the present study was the establishment of stable Huh-7 cell lines expressing structural and non structural proteins of HCV Genotype 3a Pakistani isolate obtained from chronic HCV patients...
June 28, 2011: Genetic Vaccines and Therapy
Sidra Rehman, Usman A Ashfaq, Tariq Javed
Hepatitis C virus (HCV) infection is a major worldwide problem causes acute and chronic HCV infection. Current treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus ribavirin (RBV) which has significant side effects depending upon the type of genotype. Currently, there is a need to develop antiviral agents, both from synthetic chemistry and Herbal sources. In the last decade, various novel HCV replication, helicase and entry inhibitors have been synthesized and some of which have been entered in different phases of clinical trials...
June 23, 2011: Genetic Vaccines and Therapy
Glen J McIntyre, Allison J Arndt, Kirsten M Gillespie, Wendy M Mak, Gregory C Fanning
RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated 3 shRNA co-expression methods to determine their suitability for present use; multiple expression vectors, multiple expression cassettes and single transcripts comprised of several dsRNA units (aka domains) with each being designed to a different target. Though the multiple vector strategy was effective with 2 shRNAs, the increasing number of vectors required is a major shortcoming. With single transcript configurations we only saw adequate activity from 1 of 10 variants tested, the variants being comprised of 2 - 3 different target domains...
April 17, 2011: Genetic Vaccines and Therapy
Junrong Ma, Mi Li, Longyong Mei, Qinghua Zhou, Lunxu Liu, Xijie Yu, Guowei Che
BACKGROUND: To investigate the selective killing efficacy of the double suicide genes driven by KDR promoter. MATERIALS AND METHODS: A double suicide gene system with the KDR promoter, pcDNA3-KDRp-CDglyTK, was constructed and transfected into lung cancer cell lines L9981 and NL9980, and human hepatocellular carcinoma cell line HepG2. The efficiency and specificity of the double suicide gene system were assayed by in vitro cellular proliferation and apoptosis, as well as in vivo xenograft studies...
March 22, 2011: Genetic Vaccines and Therapy
Weidong Zhang, Xueqin Cao, Dongqing Chen, Jia-Wang Wang, Hong Yang, Wenshi Wang, Subhra Mohapatra, Gary Hellermann, Xiaoyuan Kong, Richard F Lockey, Shyam S Mohapatra
BACKGROUND: Atrial natriuretic peptide (ANP) is an important endogenous hormone that controls inflammation and immunity by acting on dendritic cells (DCs); however, the mechanism remains unclear. OBJECTIVE: We analyzed the downstream signaling events resulting from the binding of ANP to its receptor, NPRA, and sought to determine what aspects of this signaling modulate DC function. METHODS: We utilized the inhibitory peptide, NP73-102, to block NPRA signaling in human monocyte-derived DCs (hmDCs) and examined the effect on DC maturation and induced immune responses...
January 10, 2011: Genetic Vaccines and Therapy
Nicolas Grandchamp, Dorothée Henriot, Stéphanie Philippe, Lahouari Amar, Suzanna Ursulet, Che Serguera, Jacques Mallet, Chamsy Sarkis
BACKGROUND: The efficacy and biosafety of lentiviral gene transfer is influenced by the design of the vector. To this end, properties of lentiviral vectors can be modified by using cis-acting elements such as the modification of the U3 region of the LTR, the incorporation of the central flap (cPPT-CTS) element, or post-transcriptional regulatory elements such as the woodchuck post-transcriptional regulatory element (WPRE). Recently, several studies evaluated the influence of the incorporation of insulators into the integrating lentiviral vector genome on transgene expression level and position effects...
January 4, 2011: Genetic Vaccines and Therapy
Shah Jahan, Baila Samreen, Saba Khaliq, Bushra Ijaz, Mahwish Khan, Muhammad Hassan Siddique, Waqar Ahmad, Sajida Hassan
BACKGROUND: Hepatitis C virus (HCV) is a major health concern with almost 3% of the world's population (350 million individuals) and 10% of the Pakistani population chronically infected with this viral pathogen. The current therapy of interferon-α and ribavirin against HCV has limited efficiency, so alternative options are desperately needed. RNA interference (RNAi), which results in a sequence-specific degradation of HCV RNA has potential as a powerful alternative molecular therapeutic approach...
2011: Genetic Vaccines and Therapy
Ambreen G Muazzam, Saleem Qureshi, Atika Mansoor, Lubna Ali, Musarrat Iqbal, Saima Siddiqi, Khalid M Khan, Kehkashan Mazhar
BACKGROUND: A recently discovered occult HCV entity reported by various investigators seems to be highly controversial. Especially, the clinical significance of these findings remains uncertain. For optimal outcome of antiviral therapy, investigation of occult HCV needs a broad-based probe in order to investigate the results of viral therapy and its host/viral interaction. The current study was aimed at determining the prevalence of occult HCV in peripheral blood lymphocytes of predominantly genotype 3 HCV-infected patients after completion of antiviral therapy and to investigate long term outcomes in the presence or absence of PBMC positivity...
2011: Genetic Vaccines and Therapy
Jung Gyu Woo, Na Young Kim, Jai Myung Yang, Sungho Shin
BACKGROUND: Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene delivery system has not yet been developed. METHODS: This study used pCMV-Luc as a model gene to investigate the biodistribution and the in vivo efficacy of arginine peptide-mediated gene delivery by polymerase chain reaction (PCR). RESULTS: Plasmid DNA was detected in all organs tested 1 h after intraperitoneal administration of arginine/DNA complexes, indicating that the arginine/DNA complexes disseminated widely through the body...
2011: Genetic Vaccines and Therapy
Mohammad Feraz Ahsan, Milind M Gore
BACKGROUND: Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used. METHODS: Three promoters known to be active in macrophage were selected and cloned in mammalian expressing vector (pAcGFP1-N1) to reconstruct (pAcGFP-MS), (pAcGFP-EMR) and (pAcGFP-B5I) with macrosialin, EmrI and Beta-5 Integrin promoters respectively...
2011: Genetic Vaccines and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"